Cancer Incidence after Initiation of Antimuscarinic Medications for Overactive Bladder in the United Kingdom: Evidence for Protopathic Bias-Reference-Cited by-同舟云学术

Cancer Incidence after Initiation of Antimuscarinic Medications for Overactive Bladder in the United Kingdom: Evidence for Protopathic Bias

Published:2017-05-29 Issue:6 Volume:37 Page:673-683
ISSN:0277-0008
Container-title:Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
language:en
Short-container-title:Pharmacotherapy

Author:

Kaye James A.¹,Margulis Andrea V.²,Fortuny Joan²,McQuay Lisa J.³,Plana Estel⁴,Bartsch Jennifer L.⁵,Bui Christine L.⁶,Perez-Gutthann Susana²,Arana Alejandro²

Affiliation:

1. Epidemiology; RTI Health Solutions; Waltham Massachusetts

2. Epidemiology; RTI Health Solutions; Barcelona Spain

3. Epidemiology, Data Analysis; RTI Health Solutions; Durham North Carolina

4. Biostatistics; RTI Health Solutions; Barcelona Spain

5. Biostatistics; RTI Health Solutions; Durham North Carolina

6. Epidemiology; RTI Health Solutions; Durham North Carolina

Funder

Astellas Pharma Global Development

Publisher

Wiley

Subject

Pharmacology (medical)

Reference25 articles.

1. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction;Haylen;Neurourol Urodyn,2010

2. The management of overactive bladder syndrome;Marinkovic;BMJ,2012

3. Clinical practice. Idiopathic urgency urinary incontinence;Nygaard;N Engl J Med,2010

4. Gormley E Lightner D Burgio K Diagosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline 2014 https://www.auanet.org/common/pdf/education/clinical-guidance/Overactive-Bladder.pdf

5. Comparative effectiveness of anticholinergic therapy for overactive bladder in women: a systematic review and meta-analysis;Reynolds;Obstet Gynecol,2015

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lessons learned from a multi‐data source research collaboration: The mirabegron post‐authorization safety study program;Pharmacoepidemiology and Drug Safety;2024-04-29

2. Identifying actionable druggable targets for breast cancer: Mendelian randomization and population-based analyses;eBioMedicine;2023-12

3. The application of lag times in cancer pharmacoepidemiology: a narrative review;Annals of Epidemiology;2023-08

4. Factors Related to Overactive Bladder-like Symptoms in Bladder Cancer;Anticancer Research;2023-07-26

5. MiR‐15b‐5p inhibits castration‐resistant growth of prostate cancer cells by targeting the muscarinic cholinergic receptor CHRM3;FEBS Letters;2023-02-20